BJH - volume 14, issue 1, february 2023
J. Blokken PhD, PharmD, T. Feys MBA, MSc
During the 64th annual meeting of ASH, again hundreds of interesting oral abstracts and poster presentations in the field of acute myeloid leukaemia were discussed. In this article, we will highlight some of the most promising data in the field of novel therapeutic agents, with interesting studies on gilteritinib and quizartinib. Furthermore, several trials assessed new induction strategies and reported on biomarker and/or minimal residual disease investigations. Finally, we discuss some practice-changing data from the ASAP and VIALE-A trials.
(BELG J HEMATOL 2023;14(1):30–5)
Read moreBJH - volume 14, issue 1, february 2023
T. Feys MBA, MSc
OVERVIEW OF BELGIAN REIMBURSEMENT NEWS
(BELG J HEMATOL 2023;14(1):36)
Read moreBJH - volume 13, issue 7, november 2022
T. Feys MBA, MSc
OVERVIEW OF BELGIAN REIMBURSEMENT NEWS
(BELG J HEMATOL 2022;13(7):284)
Read moreBJH - volume 13, issue 7, november 2022
J. Blokken PhD, PharmD, T. Feys MBA, MSc
In this section of the Belgian Journal of Hematology (BJH), we aim to provide a snapshot of pivotal studies published in recent issues of the most important international journals focusing on haematology. Importantly, the selection of the studies discussed here is the sole responsibility of the publisher and was not influenced by third parties. Do you miss an important study, or did you read a hidden jewel that deserves to be shared with your colleagues? Please, let us know (editor@bjh.be) and we will make sure to include it in the journal scan section of the next BJH issue.
(BELG J HEMATOL 2022;13(7):285–8)
Read moreBJH - volume 13, issue 6, october 2022
J. Blokken PhD, PharmD, T. Feys MBA, MSc
In this section of the Belgian Journal of Hematology (BJH), we aim to provide a snapshot of pivotal studies published in recent issues of the most important international journals focusing on haematology. Importantly, the selection of the studies discussed here is the sole responsibility of the publisher and was not influenced by third parties. Do you miss an important study, or did you read a hidden jewel that deserves to be shared with your colleagues? Please, let us know (editor@bjh.be) and we will make sure to include it in the journal scan section of the next BJH issue.
(BELG J HEMATOL 2022;13(6):256–9)
Read moreBJH - volume 13, issue 5, september 2022
J. Blokken PhD, PharmD, T. Feys MBA, MSc
During the past European Hematology Association’s annual congress (EHA 2022), four oral sessions were devoted to clinical trials and recent advances in myeloma. These sessions covered newly diagnosed multiple myeloma (MM), antibody-based therapy in relapsed/refractory (RR) MM, BCMA-directed treatment in RRMM and biology and translational research. Below, we summarise the highlights from some of the studies that were presented in each of these sessions.
(BELG J HEMATOL 2022;13(5):219–23)
Read moreBJH - volume 13, issue 4, june 2022
A. Enguita PhD, T. Feys MBA, MSc
During the presidential symposium of the 48th Annual Meeting of the EBMT (2022), the Van Bekkum Award and seven top clinical abstracts were discussed. These presentations will be covered in this report.
(BELG J HEMATOL 2022;13(4):169–73)
Read more
Top
To provide the best experiences, we and our partners use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us and our partners to process personal data such as browsing behavior or unique IDs on this site and show (non-) personalized ads. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Click below to consent to the above or make granular choices. Your choices will be applied to this site only. You can change your settings at any time, including withdrawing your consent, by using the toggles on the Cookie Policy, or by clicking on the manage consent button at the bottom of the screen.
